Key clinical point: Elevating SOX2 is necessary and sufficient on its own to promote the expression of neuroendocrine markers (NE) and confer enzalutamide resistance.
Major finding: SOX2 elevation increased the expression of several NE markers, including several neuropeptides and synaptophysin, but did not decrease the sensitivity of i-SOX2-LNCaP cells to enzalutamide.
Study details: Researchers engineered LNCaP cells for inducible overexpression of SOX2 (i-SOX2-LNCaP).
Metz EP, et al. J Cell Physiol. 2019 Oct 6. doi: 10.1002/jcp.29267.